2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1447

A Synthetic Triterpenoid CDDO-Me Prevents and Reverses Murine Lupus Nephritis
Abstract Number: 172

A Systematic Review and Meta-Analysis of Antibiotic Treatment for Reactive Arthritis
Abstract Number: 966

A Systematic Review of Evidence for the Effectiveness of Practitioner-Based Complementary and Alternative Therapies in the Management of Fibromyalgia
Abstract Number: 951

A Systematic Review of Quality of Prognosis Studies in Systemic Lupus Erythematosus
Abstract Number: 731

A Systems Biology Approach to Elucidating Pathways Active During the Development of Osteoarthritis
Abstract Number: 1456

A Tolerogenic Peptide Down-Regulates the Expression of Interferon-a in Murine and Human Systemic Lupus Erythematosus
Abstract Number: 1004

A Unique Single Nucleotide Polymorphism in the 3’ UTR of the MED29 Gene On Chromosome 19 Is Associated with the Clinical Outcome of Different Biologic Response Modifiers
Abstract Number: 56

A Validated Mathematical Model Using Electronic Health Records to Identify Rheumatoid Arthritis Patients for Observational Studies
Abstract Number: 2663

A Variant in the Osteoprotegerin Gene Is Associated with Coronary Atherosclerosis in Patients with Rheumatoid Arthritis: Results From a Candidate Gene Study
Abstract Number: 2469

A Virtual Knee Joint Replacement Clinical Endpoint Based On Longitudinal Trends and Thresholds in Koos Knee Pain and Function in Osteoarthritis Initiative Participants
Abstract Number: 1978

A Web-Based Intervention Aimed to Improve Bone Health Among Individuals On Chronic Glucocorticoids
Abstract Number: 1676

Abatacept As First Line Biological Treatment for Severe Juvenile Idiopathic Arthritis-Related Uveitis. A Multicenter Study
Abstract Number: 1289

Abatacept Biologic-Free Remission Study in Established Rheumatoid Arthritis Patients. Orion Study
Abstract Number: 2163

Abatacept Monotherapy Effectively Reduces the Frequency of Osteoclast Precursor Cells in the Peripheral Blood of Patients with Rheumatoid Arthritis and Inhibits Their Differentiation Into Osteoclasts
Abstract Number: 787

Aberrant Adipogenesis in the Pathogenesis of Scleroderma

« Previous Page
1
…
6
7
8
9
10
…
180
Next Page »

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].